⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Table S1 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma

Alyssa C. Flint Dana K. Mitchell Steven P. Angus Abbi E. Smith Waylan Bessler Li Jiang Henry Mang Xiaohong Li Qingbo Lu Brooke Rodriguez George E. Sandusky Andi R. Masters Chi Zhang Pengtao Dang Jenna Koenig Gary L. Johnson Weihua Shen Jiangang Liu Amit Aggarwal Gregory P. Donoho Melinda D. Willard Shripad V. Bhagwat D. Wade Clapp Steven D. Rhodes

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Gene set enrichment analysis of RAS signatures

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Flint et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875238ff https://doi.org/10.1158/1078-0432.27032779.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma2024
2Table S1 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma2024
3Table S1 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma2024
4Table S5 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma2024
5Table S5 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma2024